FOLH1

(redirected from Prostate-Specific Membrane Antigen)
Also found in: Acronyms.

FOLH1

A gene on chromosome 11p11.2 that encodes folate hydrolase 1, which has both folate hydrolase (FH) and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. It acts as an FH in the intestine and is required for the uptake of folate; in the brain, it modulates excitatory neurotransmission by hydrolysing the neuropeptide N-aceylaspartylglutamate (NAAG), releasing glutamate. It is highly expressed in the prostate.
Mentioned in ?
References in periodicals archive ?
Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells.
Strong prostate-specific membrane antigen marking reveals their prostatic origin (immunoperoxidase, x200).
Therefore, in such cases we begin with a broad spectrum of antibodies depending on the clinical and morphologic findings, often including pancytokeratin, p63, CK903/34[beta]E12, GATA3, PSA, prostate-specific membrane antigen, CD45, CD20, CD3, chromogranin, and synaptophysin.
1997, "Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium," Cancer Res.
Prostate-specific membrane antigen is highly specific and anchored to the cell membrane, so it is an ideal target.
Because of their high sensitivity, RT-PCR assays incorporating prostate cell-derived mRNA markers such as PSA, prostate-specific membrane antigen, and hK2 have been used for the detection of PC cells.
Nasdaq: PGNX) today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate (ADC) designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen (PSMA).
In method d, PSA and prostate-specific membrane antigen (PSMA) RT-PCR assays were performed as already described (5) after normalization of the cDNAs by (3-globin RT-PCR (9).
BIND-014 is targeted to prostate-specific membrane antigen (PSMA), a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors.
Several reverse transcriptase-polymerase chain reaction (RT-PCR) protocols are able to amplify the mRNAs encoding prostate-specific antigen (PSA) or prostate-specific membrane antigen (PSMA) in blood [1], lymph nodes [3], or bone marrow [4].
Nasdaq: PGNX) today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found on the surface of late-stage and metastatic prostate cancer and a well-known imaging biomarker for staging and monitoring therapy.

Full browser ?